We use cookies to ensure that we give you the best experience on our website. By continuing to use our site, you are agreeing to our use of cookies. You can change your cookie settings at any time if you want. Find out more in our privacy and cookies policy.
Choose a distance that'll make a difference and help us fund vital research to benefit everyone with cystic fibrosis.
The European Commission has formally approved the triple-combination therapy Kaftrio. Find out how it could help to treat people with cystic fibrosis.
Find all of our information and support available around coronavirus (COVID-19), including financial, health and shielding advice, in one place.
We're the largest charity funder of cystic fibrosis research in the UK. Explore some of our recent achievements, made possible by our supporters...
Following formal licensing by the European Commission, clinicians across the UK can now start prescribing the triple combination therapy Kaftrio to eligible people with cystic fibrosis.
Sign up to our e-newsletter to hear the latest news on what the Trust and its supporters are doing to fight for a life unlimited.
Choose a challenge that’s right for you and be a superhero at your own pace while raising as much money as you can for the Cystic Fibrosis Trust.
As the UK gets to grips with what the next phase of the coronavirus (COVID-19) pandemic may bring, our community has raised a number of concerns facing people with cystic fibrosis (CF) and their families, including returning to work and school. Keith Brownlee, Director of Policy, Programmes and Support, offers an update on some of the work the Trust has been doing to support in these areas.
We invest more money into cystic fibrosis research than any other UK organisation.
Find out more about our vision for a life unlimited by cystic fibrosis for everyone with the condition, and our strategy for getting there.
If you have a question, query, comment or suggestion, we'd love to hear from you.
Discover answers to frequently asked questions about cystic fibrosis.